SREBP1c-CRY1 signalling represses hepatic glucose production by promoting FOXO1 degradation during refeeding.
Hagoon JangGha Young LeeChristopher P SelbyGung LeeYong Geun JeonJae Ho LeeKenneth King Yip ChengPaul TitchenellMorris J BirnbaumAimin XuAziz SancarJae Bum KimPublished in: Nature communications (2016)
SREBP1c is a key lipogenic transcription factor activated by insulin in the postprandial state. Although SREBP1c appears to be involved in suppression of hepatic gluconeogenesis, the molecular mechanism is not thoroughly understood. Here we show that CRY1 is activated by insulin-induced SREBP1c and decreases hepatic gluconeogenesis through FOXO1 degradation, at least, at specific circadian time points. SREBP1c(-/-) and CRY1(-/-) mice show higher blood glucose than wild-type (WT) mice in pyruvate tolerance tests, accompanied with enhanced expression of PEPCK and G6Pase genes. CRY1 promotes degradation of nuclear FOXO1 by promoting its binding to the ubiquitin E3 ligase MDM2. Although SREBP1c fails to upregulate CRY1 expression in db/db mice, overexpression of CRY1 attenuates hyperglycaemia through reduction of hepatic FOXO1 protein and gluconeogenic gene expression. These data suggest that insulin-activated SREBP1c downregulates gluconeogenesis through CRY1-mediated FOXO1 degradation and that dysregulation of hepatic SREBP1c-CRY1 signalling may contribute to hyperglycaemia in diabetic animals.
Keyphrases
- transcription factor
- blood glucose
- type diabetes
- wild type
- glycemic control
- gene expression
- signaling pathway
- pi k akt
- poor prognosis
- high fat diet induced
- dna methylation
- dna binding
- binding protein
- blood pressure
- small molecule
- adipose tissue
- oxidative stress
- endothelial cells
- big data
- high glucose
- insulin resistance
- electronic health record
- amino acid